Access the full text.
Sign up today, get DeepDyve free for 14 days.
C. Péchoux, N. Pourel, F. Barlesi, C. Faivre-Finn, D. Lerouge, G. Zalcman, D. Antoni, B. Lamezec, U. Nestle, P. Boisselier, F. Thillays, A. Paumier, É. Dansin, K. Peignaux, J. Madelaine, E. Pichon, A. Larrouy, O. Riesterer, A. Lavolé, A. Bardet (2020)
LBA3_PR An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement: Primary end-point analysis of LungART (IFCT-0503, UK NCRI, SAKK) NCT00410683Annals of Oncology, 31
Yi-long Wu, M. Tsuboi, Jie He, T. John, C. Grohé, M. Majem, J. Goldman, K. Laktionov, Sang-We Kim, T. Kato, H. Vu, Shun Lu, K. Lee, C. Akewanlop, Chong-Jen Yu, F. Marinis, L. Bonanno, M. Dómine, F. Shepherd, L. Zeng, R. Hodge, A. Atasoy, Y. Rukazenkov, R. Herbst (2020)
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.The New England journal of medicine
M. Tsuboi, Y. Wu, Jie He, T. John, C. Grohé, M. Majem, J. Goldman, K. Laktionov, S. Kim, T. Kato, H. Vu, C. Akewanlop, C. Yu, F. Marinis, M. Dómine, F. Shepherd, C. Yan, A. Atasoy, R. Herbst (2020)
LBA1 Osimertinib adjuvant therapy in patients (pts) with resected EGFR mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrenceAnnals of Oncology, 31
B. Solomon, T. Bauer, F. Marinis, E. Felip, Y. Goto, G. Liu, J. Mazières, D-W. Kim, T. Mok, A. Polli, H. Thurm, A. Calella, G. Peltz, A. Shaw (2020)
LBA2 Lorlatinib vs crizotinib in the first-line treatment of patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC): Results of the phase III CROWN studyAnnals of Oncology, 31
short review memo (2021) 14:174–175 https://doi.org/10.1007/s12254-021-00700-w Barbara Kiesewetter Received: 4 February 2021 / Accepted: 2 March 2021 / Published online: 31 March 2021 © The Author(s) 2021 Summary This year’s virtual version of the European more the CNS efficacy of osimertinib for EGFR-pos- Society for Medical Oncology (ESMO) presidential itive patients and osimertinib was recently approved sessions included three “late breaking” non-small cell by the US Food and Drug Administration for the ad- lung cancer (NSCLC) abstracts, discussing strategies juvant therapy of NSCLC patients with EGFR exon 19 for adjuvant therapy of localized disease and up- deletion or exon 21 L858R mutations. front treatment of advanced anaplastic lymphoma kinase(ALK)-positive lung cancer. Postoperative radiotherapy for N2 disease Afurther clinically highly relevant study for localized NSCLC Keywords Non-smallcelllung cancer · Tyrosine investigated the role of adjuvant postoperative radio- kinase inhibitors · Osimertinib · Lorlatinib · Adjuvant therapy (PORT) in N2 disease, a widely performed radiotherapy practice but also matter of debate due to lack of systematic data. LungART, a European randomized CNS efficacy of adjuvant osimertinib Previously at phase III study, was the first randomized study to ASCO 2020, three years of tyrosine kinase inhibitor address this question [3]. A total of 501 patients with (TKI) osimertinib were shown to improve disease-free NSCLC stage III N2 disease were randomized either survival (DFS) compared to placebo in stage IB-IIIA to PORT with 54 Gy in 27–30 fractions or observa- NSCLC with activating epidermal growth factor recep- tion-only. Prior (neo-)adjuvant chemotherapy was tor (EGFR) mutations following standard surgery and allowed. PORT resulted in a nonsignificant improve- adjuvant therapy [1]. Late breaking abstract No. 1 dis- ment of DFS, with 30.5 months for the intervention cussed further supportive data for this strategy, with group versus 22.8 months in the control arm (hazard a focus on the central nervous system (CNS) activ- ratio [HR] 0.85, 95% CI 0.67–1.07, p = 0.16). Overall- ity of this treatment concept [2]. CNS efficacy was survival (OS) at 3 years was comparable at 66.5% for evaluated in terms of CNS-DFS as a predefined ex- PORT versus 63.8% without. As expected, the medi- ploratory endpoint of the phase III trial ADAURA. Re- astinal recurrence rate was reduced by 50% following markably, adjuvant osimertinib resulted in an 82% risk PORT but there was a higher rate of deaths reported reduction of CNS relapses (HR 0.18, 95% confidence as censoring events in the intervention group (14.6% interval [CI] 0.10–0.33, p < 0.0001). At the presented of all DFS events versus 5.3%). Furthermore, the rate data cut-off, a CNS relapse was documented in 1% of cardiotoxicity was increased in the radiotherapy (4/339) of patients in the osimertinib arm versus 10% group. One caveat, however, is the long recruitment (33/343) in the placebo cohort. The corresponding period of more than 10 years, which potentially raises CNS-DFS rate at 36 months was improved with 98% technical discussions. Key message: The presented versus 82%. Key message: These data confirm once results of the LungART study discourage use of PORT for N2 patients on a routine basis. B. Kiesewetter () Upfront treatment with lorlatinib in advanced ALK- Division of Oncology, Department of Medicine I, positive NSCLC The third late breaking abstract Medical University of Vienna, Waehringer Guertel presented data on the first line use of anaplastic 18–20, 1090 Vienna, Austria barbara.kiesewetter@meduniwien.ac.at lymphoma kinase (ALK) inhibitor lorlatinib for ad- 174 ESMO virtual congress 2020—highlights NSCLC K short review exceeds the permitted use, you will need to obtain permis- vanced ALK-positive NSCLC [4]. The randomized sion directly from the copyright holder. To view a copy of this open label phase III study CRWON evaluated the ef- licence, visit http://creativecommons.org/licenses/by/4.0/. ficacy of lorlatinib versus crizotinib in this setting. A planned interim analysis of the primary endpoint progression-free survival (PFS) was presented. Lor- References latinib significantly prolonged median PFS versus 1. Wu Y-L, Tsuboi M, He J, John T, Grohe C, Majem M, et crizotinib in previously untreated patients (median al. Osimertinib in resected EGFR-mutated non-small-cell PFS not reached versus 9.3 months, HR 0.28, 95%CI lungcancer. NEnglJMed. 2020;383(18):1711–23. 0.19–0.41). The 1-year PFS was clinically relevantly 2. Tsuboi M, Wu YL, He J, John T, Grohe C, Majem M, et al. increased with 78% versus 39%. The observed PFS LBA1 osimertinib adjuvant therapy in patients (pts) with benefit was persistent across subgroups including the resected EGFR mutated (EGFRm) NSCLC (ADAURA): cen- cohort of patients with brain metastases. Grade III tral nervous system (CNS) disease recurrence. Ann Oncol. 2020;31:S1177. and IV toxicity was slightly elevated but included 3. Le Pechoux C, Pourel N, Barlesi F, Faivre-Finn C, Ler- mostly laboratory findings such as lipid abnormalities. ouge D, Zalcman G, et al. LBA3_PR an international Patient-reported outcomes showed improvement in randomized trial, comparing post-operative conformal ra- quality of life for lorlatinib versus crizotinib (p < 0.01). diotherapy (PORT) to no PORT, in patients with completely Key message: These results suggest a high activity of resected non-small cell lung cancer (NSCLC) and mediasti- lorlatinib front-line; longer follow-up data and com- nalN2involvement: primaryend-pointanalysisoflungART parison with further next generation ALK inhibitors (IFCT-0503, UK NCRI, SAKK) NCT00410683. Ann Oncol. 2020;31:S1178. will be important for the definitive positioning of this 4. Solomon B,Bauer TM,DeMarinis F, Felip E,Goto Y,Liu G, TKI. et al. LBA2 lorlatinib vs crizotinib in the first-line treatment Funding Open access funding provided by Medical University of patients (pts) with advanced ALK-positive non-small cell of Vienna. lung cancer (NSCLC): results of thephaseIII CROWN study. AnnOncol. 2020;31:S1180. Conflict of interest B. Kiesewetter declares that she has no competing interests. Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional Open Access This article is licensed under a Creative Com- affiliations. mons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to For latest news from interna- the Creative Commons licence, and indicate if changes were tional oncology congresses see: made. The images or other third party material in this article http://www.springermedizin.at/ are included in the article’s Creative Commons licence, unless memo-inoncology indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or K ESMO virtual congress 2020—highlights NSCLC 175
memo - Magazine of European Medical Oncology – Springer Journals
Published: Jun 1, 2021
Keywords: oncology; medicine/public health, general
You can share this free article with as many people as you like with the url below! We hope you enjoy this feature!
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.